1 published article · Updated continuously
24 trials tracked for Nasal polyps: 14 in phase 3 or 4 and 7 with published results. The most-cited published study has 125 citations.
Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Several biologic and pharmacological interventions have demonstrated efficacy in managing nasal polyps. Mepolizumab significantly improved total endoscopic nasal polyp (NP) scores at week 52 [3, 10], reduced nasal obstruction scores 10, and decreased the number of patients requiring surgery 20. Depemokimab also showed significant improvements in NP scores [7, 8] and mean nasal obstruction scores [7, 8] over a 52-week period. Omalizumab demonstrated statistically significant reductions in Nasal Polyp Score (NPS) [4, 5, 9], average daily nasal congestion score (NCS) [4, 5, 9], and improved sense of smell scores [4, 5].
Mometasone Furoate Nasal Spray (MFNS) was shown to significantly reduce both congestion/obstruction scores and total polyp size scores 13. Fluticasone Propionate resulted in significant improvements across multiple metrics including SNOT-22 total scores and Lund-Mackay scores 12. In surgical settings, oxymetazoline improved surgical field visualization 1, while remifentanil significantly reduced the time to achieve a low intraoperative bleeding score compared to control 2. Additionally, the S8 Sinus Implant was associated with significant reductions in bilateral polyp grade and ethmoid sinus obstruction 6.
AI synthesis of 8 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Yes, several genes and genetic pathways are linked to chronic rhinosinusitis with nasal polyps, including FOXP3, STAT1, and miRNAs like miR-130a-3p and miR-196b-5p.
Full answer →